ESH AL 2018 | FLT3 inhibitors in the treatment of AML
Farhad Ravandi
Farhad Ravandi, MD, from the University of Texas MD Anderson Cancer Center, Houston, TX, describes which FLT3 inhibitors his group uses to treat different subsets of patients with acute myeloid leukemia (AML ). This video was recorded at the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary.
Related videos
4:20
Projections from real world evidence of CLL management
Robin Foà
1:50
Current ERIC research in the CLL genomics field
Richard Rosenquist
1:52
ERIC's first International Meeting and plans for the future
Paolo Ghia
3:08
Resistance mechanisms in CLL
Richard Rosenquist
3:18
Opinion on MRD in CLL: routine use or clinical trials?
Kanti Rai
